We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Today, Plantsulin blends this century-old discovery with modern scientific validation to offer a fast, convenient "whole-body ...

Announcing a new article publication for BIO Integration journal.   Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...

This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens ...